Centro De Inmunologia Molecular

Centro De Immunologia Molecular

Belinda Sánchez Ramírez

Circe Mesa Pardillo

Luis Enrique Fernández Molina

Narjara González Suárez

Lisset Chao García

Diana Rosa Hernández Fernández

Mabel Cruz Rodríguez

Jesús Arturo Junco Barranco

Audry Fernández Gómez

Ángel Alexis Manso Vargas

Blanca Idelmis Tolón Murguía

Miguel Antonio López López

Vicente Guillermo Verez Bencomo

Dayana Pérez Martínez

Gretchen Bergado Báez

Rolando Perez Rodriguez

Irene Beausoleil Delgado

Gilda Nurez Gandolf

Anabel De La Barrera Aira

Eduardo Suarez Peztana

Gisela Gonzalez Marinello

Joel De Leon Delgado

Augustin Bienvenido Davila

Yildian Diaz Rodriguez

Gretchen Báez Bergado

Eduardo Raul Suarez Pestana

Arianna YGlesias Rivera

Amelia Gutiérrez Pérez

Greta Garrido Hidalgo

Alejandro López Requena

Rolando Pérez Rodríguez

This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) ofin solutions containing fully synthetic variants of the GM3 ganglioside.

Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines

The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins ofand the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.

Method for the treatment of patients with carcinomas

This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) ofwith gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized. The essence of the invention consists in describing compositions that triggers immunogenicity in low immunogenic antigens, such as growth factor receptors, without imparting structural changes therein. Particularly, this invention refers to preparation of immuno-stimulating compositions capable of generating antigen-specific immune responses, even in immuno-compromised hosts, such as those suffering form cancer or viral or bacterial chronic infections. In said patients, the administration of the vaccine compositions described in this invention has lead to the reestablishment of the functionality of the immune system. Vaccine compositions of this invention can be used to protect or treat infectious, or auto-immune diseases.

Preparations that potentiate immunogenicity in low immunogenic antigens

The invention provides novel uses of EGF and vaccine compositions comprising EGF. In particular, autologous EGF, or a fragment or a derivative thereof, is used as an active immunization against the proliferation of EGF-dependent tumors, or other EGF-dependent diseases. Autologous EGF is preferably coupled to a carrier protein, such as tetanus toxoid or Cholera toxin B chain. The vaccine compositions according to the invention will usually comprise an adjuvant such as aluminum hydroxide.

Vaccine composition comprising autologous epidermal growth factor or a

Growing community of inventors

Havana, Cuba

Belinda Sánchez Ramírez